Loading…
Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2
[...]all humans lack the αGal glycan motif and possess natural anti-αGal antibodies generated in response to bacteria of the microbiota that express similar glycans [2]. [...]blood group O individuals were at a much lower risk of being infected than non-O individuals in a Hong Kong 2003 SARS hospita...
Saved in:
Published in: | PLoS pathogens 2020-05, Vol.16 (5), p.e1008556-e1008556 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | [...]all humans lack the αGal glycan motif and possess natural anti-αGal antibodies generated in response to bacteria of the microbiota that express similar glycans [2]. [...]blood group O individuals were at a much lower risk of being infected than non-O individuals in a Hong Kong 2003 SARS hospital outbreak [15], and a similar trend has just been observed for COVID-19 in China [16]. [...]blood group O individuals would be at a lesser risk of being infected than non-O individuals due to blocking of potential transmission events from either A, B, or AB individuals, providing anti-A or anti-B titers are of sufficient magnitude (Fig 1). In the presence of high-titered anti-A and anti-B antibodies, transmissions represented by dashed arrows should be completely ablated. https://doi.org/10.1371/journal.ppat.1008556.g001 We therefore hypothesize that as they are produced in cells coexpressing the ACE2 receptor and either the αGal, NeuGc, or A/B blood group antigens, both SARS-CoV and SARS-CoV2 harbor the corresponding glycan epitopes. Because of the natural immune response against these epitopes, the αGal and NeuGc xenoantigens would contribute to prevent cross-species transmission from nonprimate mammals to humans, while A/B blood group antigens would contribute to decrease and slow between-human transmission. |
---|---|
ISSN: | 1553-7374 1553-7366 1553-7374 |
DOI: | 10.1371/journal.ppat.1008556 |